Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, announced that Glenmark Generics, the subsidiary of the company has been granted final approval for its abbreviated new drug application (ANDA) from the United States Foods and Drug Administration (USFDA). The approval is for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.

Omeprazole DR Capsules are indicated for the short-term treatment of active duodenal ulcer in adults. The approval is for the 10, 20 and 40 mg strengths of Omeprazole. According to IMS Health sales date for the 12 month period ending September 2014, Omeprazole garnered annual sales of approximately USD 520 million.

Shares of the company gained Rs 10.5, or 1.44%, to trade at Rs 739.10. The total volume of shares traded was 16,057 at the BSE (11.00 a.m., Wednesday).